Nobel laureate heads up NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 6
Volume 19
Issue 6

Harold E. Varmus, MD, has been nominated by President Barack Obama to serve as the director of the NCI.

Harold E. Varmus, MD, has been nominated by President Barack Obama to serve as the director of the NCI. Dr. Varmus most recently served as president and CEO of Memorial Sloan-Kettering Cancer Center in New York. Dr. Varmus, J. Michael Bishop, MD, and colleagues won the 1989 Nobel Prize for Physiology or Medicine when they demonstrated the cellular origins of the oncogene of a chicken retrovirus. This led to the isolation of cellular genes that control growth and development and are frequently mutated in human cancer. The NCI directorship will be Dr. Varmus' second go-round heading up a federal institution: He served as director of the NIH from 1993 to 1999.

Articles in this issue
Nobel laureate heads up NCI
Cleveland Clinic nets federal funds for research facility revamp
Diabetes drug acts as chemopreventive in smokers
FTC extends deadline for Red Flags Rule on patient privacy
From the ONI archives: Ofatumumab turns in encouraging results in pretreated CLL
Studies strengthen connection between mammographic breast density and a woman’s risk of breast cancer
Excess weight, smoking may influence risk of disease relapse after prostate cancer treatment
Breakthrough cancer-related pain: The truth hurts
African-American genetic mutations pose Rx challenge
African-American genetic mutations pose Rx challenge
Personalized medicine advances in non-small–cell lung cancer treatment
PET unable to reliably identify post-Rx colon mets
Medicare study questions use of high-tech cancer imaging
Who's News
Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content
The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line non-squamous NSCLC.

Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC

Roman Fabbricatore
November 30th 2025
Article

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?

Tim Cortese
November 29th 2025
Article

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.